Cerity Partners LLC Lowers Position in ICU Medical, Inc. (NASDAQ:ICUI)

Cerity Partners LLC decreased its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 5.7% during the fourth quarter, HoldingsChannel reports. The firm owned 9,283 shares of the medical instruments supplier’s stock after selling 563 shares during the period. Cerity Partners LLC’s holdings in ICU Medical were worth $1,440,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Norges Bank purchased a new position in ICU Medical during the fourth quarter valued at approximately $40,151,000. Raymond James Financial Inc. bought a new stake in ICU Medical during the 4th quarter valued at $10,003,000. JPMorgan Chase & Co. boosted its position in ICU Medical by 7.4% during the 4th quarter. JPMorgan Chase & Co. now owns 708,382 shares of the medical instruments supplier’s stock valued at $109,920,000 after acquiring an additional 49,108 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of ICU Medical by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier’s stock valued at $99,687,000 after acquiring an additional 48,106 shares during the period. Finally, Proficio Capital Partners LLC purchased a new stake in shares of ICU Medical during the 4th quarter worth $5,779,000. Institutional investors own 96.10% of the company’s stock.

ICU Medical Trading Down 0.3 %

Shares of NASDAQ:ICUI opened at $138.67 on Friday. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.03. The firm has a market capitalization of $3.40 billion, a P/E ratio of -30.34 and a beta of 0.86. The business’s 50-day moving average is $146.73 and its 200 day moving average is $160.03. ICU Medical, Inc. has a 1 year low of $93.36 and a 1 year high of $196.26.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ICUI. Raymond James set a $97.00 target price on ICU Medical in a research note on Wednesday, March 12th. StockNews.com raised shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday. Finally, Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a research report on Tuesday, April 8th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average price target of $168.67.

ICU Medical Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.